Kornimate/medical-research-clean huggingface dataset:
the long term effect of low dose aspirin on uric acid in chinese patients with coronary artery disease（aurora）

Conditions: Coronary Artery Disease; Hyperuricemia

Summary: the deleterious effects of hyperuricemia (hua) on cardiovascular disease (cvd) were well established. aspirin is the most commonly prescribed antiplatelet agent for primary or secondary prophylaxis of cvd. only a few short-term studies in the elderly suggested low-dose aspirin, e.g., 75-100 mg/day, increases serum urate by reducing urinary uric acid excretion. however, monitoring of renal function is currently not recommended. little is known about the long-term effect of low dose aspirin on uric acid. the principal aim of this prospective cohort study therefore is to evaluate the renal effects of long-term aspirin (100 mg/d) administration in chinese patients with coronary artery disease or other cvds.


Eligibility criteria:
inclusion criteria: 1. patients with coronary artery disease (cad) who underwent (percutaneous transluminal coronary intervention) pci therapy, documenting angiographically at least one vessel stenosis ≥50% among major coronary arteries (left main, left anterior descending, left circumflex or right coronary artery) , manifesting clinically as latent cad, stable cad, unstable cad, and acute myocardial infarction. 2. patients with cad without pci therapy. they document angiographically at least one vessel stenosis ≥50% among major coronary arteries (left main, left anterior descending, left circumflex or right coronary artery) , and classified clinically as latent cad, stable cad, unstable cad. 3. patients without cad who needs antiplatelet therapy for prophylaxis of ascvd, documenting angiographically no vessel stenosis ≥50% among any of major coronary arteries (left main, left anterior descending, left circumflex or right coronary artery). exclusion criteria: 1. patients with severe conditions with life expectancy less than 12 months. 2. patients with malignant tumor. 3. severe kidney disease: patients with acute kidney injury, nephritic syndrome, renal replacement therapy, kidney transplant or egfr \<30 ml/min/1.73 m2. 4. contraindicated to antiplatelet therapy because of acute bleeding. 5. patients who formerly administrated aspirin for at least one week or withdrawal of aspirin less than one month before enrollment. 6. patients who formerly administrated ua lowering agents at least one month before enrollment. 7. patients who formerly administrated, stopped or titrated doses of any of the following drugs at least one month before enrollment: losartan, irbesartan, fenofibrate, thiazide and loop diuretics. 8. patients who administrated ticagrelor as antiplatelet agent one month before enrollment or since then. -

Keywords: aspirin; coronary artery disease, uric acid
gerontological telemonitoring of older adults living in nursing homes with covid-19 disease

Conditions: Coronavirus Infection

Summary: since the last 3 months the world copes with the novel coronavirus disease : covid-19 emerged in china in the end of 2019. who declared the pandemic situation as a public health emergency around the world on january 2020. firsts studies emphasized on higher risk to older adults to experience serious health consequences : hospitalizations and mortality, due to multimorbidity and multimedication. nursing home resident are particulary frailer and vulnerable.


Eligibility criteria:
inclusion criteria: * nursing home resident with covid disease rt-pcr or chest ct or rapid test * nursing home resident with covid-19 disease symptoms : * fever * cough * dyspnea * spo2\<95% in ambient air (or \<91% in copd patient) * diarrhea * fall or balance disorder * confusion exclusion criteria: * age \< 75 years * patient in respiratory distress * no consent

Keywords: covid-19, early gerontologic healthcare
effectiveness of prophylactic bolus ephedrine versus norepinephrine for management of post spinal hypotension

Conditions: Comparing Ephedrine With Norepinephrine for Mangement Postspinal Hypotension

Summary: this study was conducted to compare the effectiveness of ephedrine versus norepinephrine for management of hypotension after spinal anesthesia for mothers undergoing elective cesarean section


Eligibility criteria:
inclusion criteria: * asa class ii and ages ranging from 18-35 years were included in the study exclusion criteria: * pregnant women with preeclampsia/eclampsia, baseline hypertension (sbp\> 140 mm hg), bmi\> 30 kg/m2, failed spinal, spinal anaesthesia converted to general anaesthesia, contraindication for spinal anaesthesia and mother with cardiovascular, renal or hepatic disease.
customized shoe-padding orthotics for plantar fasciitis

Conditions: Plantar Fasciitis of Both Feet

Summary: while human body receives large external force or motions, minor injuries to the soft tissues will be produced and will lead to acute or chronic inflammation reactions. plantar fasciitis is the most common foot diseases in normal population. plantar fascia is a tight band-like soft tissue that crosses between the bony surfaces of the bottom of the foot with thick ligament-like structure substantially. various reasons will induce the happening of plantar fasciitis including native bone structure, aging, athletic motions and injuries. indeed, diagnosis of chronic heel pain remains challenging due to the complex structures of the foot. therefore, it is widely accepted that diagnostic imaging such as ultrasound and computed tomography offer important orthopedic information for clinical assessments of soft tissues and bone. even though there is no single treatment shows the highest level of evidence for plantar fasciitis, wearing of insoles or orthotics are highly suggested for clinical therapy. common custom-made insoles are manufactured with polymeric materials based on standing foot-pressure distribution. however, this method strongly depends on experience of doctors or physical therapists and usually time-consuming. in addition, modern medical researches tend to combine the information of both soft (pressure distribution) and hard (orthopedic) tissues for designing of orthotics and other medical assistive devices because of the complicity of the limb motion and structures. therefore, investigators aim at developing integrated 3d system that provides a 3d limb data model with high-resolution appearance scanning and orthopedic information for designing of medical assistant devices. this model composes of 3d surface scanning, 3d bony structure scanning, and soft tissues characteristic mechanical properties. by developing this system, the 3d model is also highly applicable to the other parts of human assistant devices. it will bring the enormous impact to the associated medical field and create excellent economic value.


Eligibility criteria:
inclusion criteria: * 20-80 years old * plantar fasciitis patients recommended to use shoe-padding orthotics for treatment exclusion criteria: * plantar fasciitis caused by specific reasons, eg. trauma, bone spur, acute bursitis. * not taiwanese

Keywords: plantar fascitis orthopedic 3d surface scanning
clinical outcomes of modified del nido cardioplegia in adult and pediatric cardiac surgery

Conditions: Cardiac Events

Summary: "introduction: modern cardiac surgery prioritizes myocardial protection, incorporating various strategies including cardioplegia to preserve heart function during surgery. the del nido (dn) cardioplegia solution, initially for pediatric use, shows promise in adult surgeries due to its longer protection duration and reduced re-dosing needs. however, its efficacy in adults remains under-researched.

this study aims to evaluate the clinical outcomes of modified del nido cardioplegia in adult and pediatric cardiac surgeries, comparing intraoperative and postoperative metrics to provide evidence on its efficacy and safety. to assess the clinical outcomes of modified del nido cardioplegia in cardiac surgeries across different age groups, focusing on myocardial protection, hemodynamic stability, surgical outcomes, recovery, and complications.

Eligibility criteria:
inclusion criteria: * all pediatric patients with congenital heart diseases. * individuals who are capable of giving their informed permission; * stable patients undergoing surgical procedures that involve cardiopulmonary bypass and cardiac arrest; * isolated cabg surgery, or simultaneous cabg; * isolated single-valve surgery or multiple value procedures. exclusion criteria: * previous cardiac surgery * patients with preoperative inotropic pharmacologic support * patients receiving preoperative mechanical circulatory support, * patients with an implanted pacemaker or implantable cardioverter-defibrillator, * patients undergoing cardiac surgical procedures * patients who underwent off-pump or beating heart cabgs * ventilation for the night was scheduled because of severe pulmonary arterial hypertension. * mediastinal drain causing a delay in extubation, or the need to reopen for bleeding or tamponade.
long acting phosphodiesterase 5 inhibitors as add-on therapy for patients with pulmonary hypertension treated with prostanoids.

Conditions: Pulmonary Arterial Hypertension

Summary: pulmonary arterial hypertension is a chronic disease of the lung blood vessels resulting in constriction and high pressures. treatment is given with a variety of drugs including the prostanoid class (e.g. epoprostenol, iloprost and the phosphodiesterase 5 (pde-5) inhibitors (e.g. sildenafil). although these drugs are known to be effective alone, little is known about combining them together in various combinations. in this trial we will add a long-acting pde-5 inhibitor to the treatment of patients with pulmonary arterial hypertension who currently are receiving only a prostanoid drug.


Eligibility criteria:
inclusion criteria: * all patients must satisfy current diagnostic criteria for pulmonary artery hypertension based on their historical right heart catheter data (within 3 years of study enrollment): mean pap \>25mmhg at rest or \>30mmhg with exercise, by a pcwp\ 3 wood units. * currently stable for at least 3 months on prostanoid monotherapy (epoprostenol iv or iloprost inhaled). * willing and able to participate in all study follow-up procedures. * new york heart association (nyha) class ii-iv. * six minute walking distance between 100-450 meters at the baseline assessment. * women of child-bearing age must demonstrate adequate contraception or undergo a pregnancy test. * patients with congenital heart disease are eligible for inclusion. exclusion criteria: * functional class nyha class i. * pah due to chronic pulmonary thromboembolic disease, left heart disease, chronic lung diseases (vc or fev1 \< 60% of predicted) or chronic hypoxia. * acute intercurrent illness requiring hospital admission in the month proceeding screening. * any non-pah medical condition likely to interfere with participation in evaluation of study endpoints, e.g. musculoskeletal disorders. * any uncontrolled or terminal non-pah medical condition likely to interfere with completion of the study, according to the judgment of the study physician. * concomitant therapy with drugs known to interact adversely with the study drug. * chronic renal failure - creatinine clearance \<50ml/min as calculated with the cockcroft equation. * current participation in another clinical trial. * pregnancy or planned pregnancy during the study period.
orbital fractures registry

Conditions: Orbital Fractures; Blow Out Fracture of Orbit

Summary: approximately 300 patients presenting orbital blow-out fracture will be enrolled prospectively in this registry. all patients, surgically and nonsurgically treated as per standard (routine) of care will be followed-up (fu) within the registry for a period of 6 months.

approximately 300 patients presenting with a displaced orbital fracture (ofx) in the floor and/or medial wall (blow-out fracture) will be enrolled prospectively in this registry. all patients, surgically and nonsurgical treated will be followed-up (fu) within the registry. fu period for all patients will include assessments post-treatment at 6 weeks, 3 months and 6 months as corresponding with the local standard (routine) visit schedule at each participating clinic. data collection includes patient and fracture details, treatment details, functional, clinical and patient-reported outcomes and anticipated or procedure- and implant-related adverse events (ie, complications). computer tomography (ct) scans or cone beam-ct (cbct) scans taken as per standard of care will be collected within the registry.

Eligibility criteria:
inclusion criteria: * age 18 years or older at the time of the injury * patients with a dislocated fracture of the inferior and/or medial orbital wall, either * diagnosed at the study site via ct or cbct within 2 weeks of the date of the injury, or * who will undergo secondary reconstruction exclusion criteria: * bilateral orbital fracture * concomitant displaced fracture(s) of the orbital roof or any other area of the orbit * concomitant ruptured globe * displaced fracture of the malar bone * displaced midface fracture * displaced nasoorbitoethmoidal (noe) fracture or complex zygoma fractures * presence at the time of enrollment of any disease with influence on eye motility (eg, strabismus, myasthenia gravis, graves' ophthalmopathy) * previous radiotherapy in the orbital region * participation in any other medical device or medicinal product study within the previous month(s) that could influence the results of the present study

Keywords: fracture fixation orbital implant midface fracture diplopia
injectable filler for facial soft tissue augmentation

Conditions: Wrinkles

Summary: the purpose of this study is to assess the safety and performance of hydroxytite in all subjects who have received sub dermal or deep dermal injections.


Eligibility criteria:
inclusion criteria: * patient is over 18 years of age * patient received hydroxytite injection(s). exclusion criteria: • patient declines to participate in the study

Keywords: nasolabial folds marionette lines cheek bones jaw lines
quantitative ultrasound for diagnosing hepatic steatosis in nonalcoholic fatty liver multicenter study

Conditions: Diagnoses Disease

Summary: to evaluate the diagnostic performance of quantitative ultrasound parameters for assessing hepatic steatosis in non-alcoholic fatty liver disease using histologic results as reference standard


Eligibility criteria:
inclusion criteria: * clinically suspected or proven nonalcoholic fatty liver disease (nafld) * patients who are scheduled hepatic parenchymal biopsy for suspected liver disease or hepatectomy for living donor liver donation * aged ≥ 18 years who are willing and able to complete all procedures exclusion criteria: * excessive alcohol consumption within 2 years (40g/day for men, 20g/day for women) * clinical, laboratory, or histologic evidence of a liver disease other than nafld, including viral hepatitis, autoimmune hepatitis, or genetic or acquired disorders * use of steatogenic or hepatotoxic medication * evidence of decompensated liver disease * history of liver surgery * any other condition believed by investigator to affect a patients' compliance, or completion of the study
impact of the early use of high flow nasal cannula in patients with post-traumatic lung contusion, a randomized clinical trial

Conditions: Traumatic Lung Injury

Summary: we hypothesize that early and continuous administration of oxygen via high flow nasal cannula in patients with lung contusion and non-severe acute lung injury might reduce the incidence of intubation and hold the deterioration of pulmonary functions.


Eligibility criteria:
inclusion criteria: willing and able to provide written informed consent prior to performing study procedures, currently hospitalized and requiring medical care for blunt chest trauma, within 24h of trauma exclusion criteria: * face trauma or surgery, airway obstruction, known to have chronic chest condition
evaluating obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations

Conditions: Pancreatic Cancer

Summary: this study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.

this observational study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations consisting of adult males or females, 18 years of age or older, who self-report as african american (aa) or non-hispanic white (nhw), and present to the gastrointestinal (gi) clinic, surgery, or endoscopy at a participating florida pancreas collaborative (fpc) site or university of mississippi medical center (ummc) with a clinical suspicion or diagnosis of a pancreatic tumor. this study will also include patients who have been previously recruited as part of the fpc study. our central hypothesis is that adipose tissue (at) dysfunction contributes to malignant transformation, therapeutic resistance, and poor survival among obese aa pancreatic ductal adenocarcinoma (pdac) cases and such dysfunction will be characterized by unique biology. the primary objective of this multi-institutional and multidisciplinary translational study is to identify a molecular and imaging profile unique to paired pdac tumors and at from aa and harness biological observations to predict therapeutic response and target novel obesity-mediated mechanisms of pdac development and progression using in vitro, ex vivo, and in vivo techniques and new combinations of drug agents.

Eligibility criteria:
inclusion criteria: * adults 18 years of age or older at time of signing informed consent * patients who self-report as african american, non-hispanic white * patients who present to the gastrointestinal (gi) clinic, surgery, or endoscopy at a participating florida pancreas collaborative (fpc) site or the university of mississippi medical center (ummc) with a clinical suspicion or diagnosis of a pancreatic tumor. exclusion criteria: * patient under 18 years of age * has no suspicion or diagnosis of a pancreatic cancer or tumor * self-reported race/ethnicity other than african american or non-hispanic white.

Keywords: pancreas biomarkers health disparities
ucn-01 in treating patients with advanced or metastatic kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of ucn-01 in treating patients who have unresectable stage iii or stage iv kidney cancer.

objectives: * determine the efficacy of ucn-01, in terms of time to objective progression, in patients with stage iv or unresectable stage iii renal cell carcinoma. * determine the objective response rate in patients treated with this drug. outline: patients receive ucn-01 iv over 3 hours on day 1. courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 21-61 patients will be accrued for this study within 15 months.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed stage iv or unresectable stage iii renal cell carcinoma * metastatic disease must be amenable to biopsy or appropriate for nephrectomy before study therapy * at least 1 unidimensionally measurable lesion * at least 20 mm by conventional techniques or at least 10 mm by spiral ct scan * no known prior or concurrent cns metastases patient characteristics: age: * 18 and over performance status: * ecog 0-2 or * karnofsky 60-100% life expectancy: * more than 3 months hematopoietic: * wbc at least 3,000/mm\^3 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin normal * ast/alt no greater than 2.5 times upper limit of normal renal: * creatinine normal or * creatinine clearance at least 60 ml/min cardiovascular: * no history of clinically significant coronary artery disease * no symptomatic cardiac dysfunction * no symptomatic congestive heart failure * no unstable angina pectoris * no cardiac arrhythmia pulmonary: * no symptomatic pulmonary dysfunction other: * no prior allergic reactions to compounds of similar chemical or biological composition to ucn-01 * no other uncontrolled concurrent illness * no active or ongoing infection * no known immune deficiency * no psychiatric illness or social situation that would preclude study compliance * no insulin-dependent diabetes mellitus * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 6 months after study participation prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered endocrine therapy: * not specified radiotherapy: * at least 4 weeks since prior radiotherapy and recovered * no prior mediastinal radiation surgery: * see disease characteristics * at least 4 weeks since prior nephrectomy other: * no more than 2 prior systemic therapies for metastatic renal cell carcinoma * no other concurrent investigational agents

Keywords: stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer